Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries

Mark, G.; Lanzinger, Stefanie; Sziegoleit, Stefan; Putz, Franz Josef; Durmaz, Mesut; Borscheller, M; Danne, Thomas; Seufert, Jochen; Holl, Reinhard W.; Bramlage, Peter

doi:10.1007/s12325-019-00983-w

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, some recent RWS reported that patients with T1D using IGla-300, transferred from another basal insulin, have significant reductions in HbA1c levels,17 22 23 with no change in weight17 22 23 or DIDR 17 23 30. However, other studies in routine practice settings have reported higher DIDR ranged from 6.5% to 10.1% after switching to U300 from U100, mainly in the first 6 months 19 20 29. On the other hand, in RCTs comparing IDeg with either glargine or detemir in patients with T1D, IDeg daily doses at end point are usually lower than comparators 13 26 37.…”

Section: Discussionmentioning

confidence: 99%

“…The second-generation long-acting insulin analogs, glargine U300 UI/mL (IGla-300) and degludec (IDeg), were introduced in 2015 and have shown, in randomized controlled trials (RCTs), an increased stability, which translates to an increased flexibility in timing of administration12 13 and reduced risk of hypoglycemia compared with glargine U100 UI/mL insulin (IGla-100),14 15 results that have been reproduced in several real-world studies (RWS),16–21 although others have reported no differences in hypoglycemia between first-generation and second-generation basal analogs 22–25. Otherwise, a number of RCTs and RWS have reported higher daily insulin doses requirements (DIDR) with IGla-30012 15 20 and lower with IDeg,13 14 18 21 compared with IGla-100, although some studies failed to detect these difference 17 23–31…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Insulin Doses Requirements in Patients with Type 1 Diabetes Using Glargine U300 or Degludec in Routine Clinical Practice

Laureano

Fernández-Ladreda

Millán

et al. 2021

Journal of Investigative Medicine

View full text Add to dashboard Cite

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Insulin Doses Requirements in Patients with Type 1 Diabetes Using Glargine U300 or Degludec in Routine Clinical Practice

Laureano

Fernández-Ladreda

Millán

et al. 2021

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…Further, the real-world evidence from across the world supports the above-discussed benefits of Gla-300 in T1DM management along with the highest persistence rate [ 50 - 52 ]. In particular, Gla-300 has been shown to be effective in substantial improvement in HbA1c reduction with reduced incidence of nocturnal or severe hypoglycemia episodes and diabetic ketoacidosis [ 53 , 54 ].…”

Section: Gla-300 In Special Populationmentioning

confidence: 95%

Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review

Ghosh

Kalra

Bantwal

et al. 2023

CDR

View full text Add to dashboard Cite

Background and Aims: Hypoglycemia and insulin-related adverse events are crucial barriers to effective diabetes management, particularly in the elderly, people with renal impairment, people with diabetes fasting during Ramadan, or people with type 1 diabetes mellitus (T1DM). There is a scarcity of clinical and real-world evidence assessing the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) in these special populations. To understand the entirety of evidence, this mini-review elaborates on the use of Gla-300 in diabetes management among special populations. Methods: Clinical and real-world evidence related to the use of Gla-300 among special populations with diabetes were retrieved using PUBMED and Google Scholar. Results: Gla-300 has shown improved glycemic control with stable insulin action and low risk of hypoglycemia in diverse groups with diabetes. It also appears to have an acceptable safety profile during Ramadan fasting. However, adequate monitoring and adjustment of insulin dose on an individual basis should be considered. Conclusion: Gla-300 is a second-generation basal insulin with proven benefits of reduced risk of hypoglycemia and improved glycemic control in special populations of people with diabetes.

show abstract

Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study

Basu

Shao

Luo

et al. 2021

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries

Cited by 5 publications

References 34 publications

Insulin Doses Requirements in Patients with Type 1 Diabetes Using Glargine U300 or Degludec in Routine Clinical Practice

Insulin Doses Requirements in Patients with Type 1 Diabetes Using Glargine U300 or Degludec in Routine Clinical Practice

Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review

Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study

Contact Info

Product

Resources

About